Brief: TransCode Therapeutics And Quantum Leap Healthcare Collaborative Launch A Phase 2A Dose-Expansion Trial With TTX-MC138, Following Positive Readouts From TransCode's Phase 1 Trial
11/12/2025 13:08
Dec 11 (Reuters) - Transcode Therapeutics Inc RNAZ.O: TRANSCODE THERAPEUTICS AND QUANTUM LEAP HEALTHCARE COLLABORATIVE LAUNCH A PHASE 2A DOSE-EXPANSION TRIAL WITH TTX-MC138, FOLLOWING POSITIVE READOUTS FROM TRANSCODE'S PHASE 1 TRIAL TRANSCODE THERAPEUTICS INC - PHASE 2A TRIAL TO BEGIN IN 2026 Source text: ID:nPnbrvS72a Further company coverage: RNAZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors